NTRK1 and head and neck cancer: Therapies currently approved by the FDA for the treatment of advanced metastatic head and neck cancer include cetuximab, an antibody that blocks the receptor tyrosine kinase (RTK) epithelial growth factor receptor (EGFR), and it is usually combined with other radiotherapy drugs for the treatment of advanced locally metastatic head and neck cancer [3, 4].